

**2nd BCLT
Advanced Life Sciences Institute**

**Impacts of AI's Rapid Rise
in the Life Sciences**

May 2024


BCLT BY THE NUMBERS | *Unrivaled Impact in Tech Law*

#1 Ranked IP law program
20 years by US News



15,000+ Hours of free CLE
instruction provided

40+ Law & tech courses
planned for 2023-2024



9 BCLT faculty-authored textbooks



15 Major conferences
planned for 2023-2024

20+ Other expert-level
events planned for
2023-2024

19 Faculty directors teaching full time and
writing on law and tech issues

3 Faculty Directors ranked
among top 5 most cited IP
scholars




35 Practitioner instructors teaching
advanced law and technology courses



13 Tech-focused Student
Groups

26 Years BCLT has been
collaborating with
Federal Judicial Center



850+ Federal judges
trained at the BCLT/
FJC IP seminar

Michelle Chen

Dr. Michelle Chen is the Chief Business Officer at Insilico Medicine. She brings more than 20 years of extensive experience in both the biopharma and technology industries. Prior to Insilico Medicine, she was the Senior Vice President of Corporate Development and Discovery Business Development for WuXi Biologics where she led multiple M&A and licensing transactions, drove strategic partnerships and joint ventures with external biopharma partners, set up a new company in Europe and fostered investor relations in the United States and Europe. As a biotech executive, Dr. Chen has worked at top pharmaceutical companies such as Roche, Merck, and BioMarin, as well as biotech and technology companies in roles ranging from business and corporate development, product marketing, and R&D with a strong track record of success. She has a Ph.D. in Biochemistry from the University of Washington, did postdoctoral work at UCSF, and received Bioinformatics training at Stanford.



Insilico Medicine

Connect with [Michelle](#) on LinkedIn

Berkeley Center for Law
& Technology

at Berkeley Law

Hans Sauer

Hans Sauer is deputy general counsel and Vice President for Intellectual Property for the Biotechnology Innovation Organization (BIO), a major trade association representing more than 1,100 biotechnology companies from the medical, agricultural, environmental, and industrial sectors. At BIO, he advises the organization's board of directors, amicus committee, and various staff committees on patent and other intellectual-property-related matters. Before taking his current position at BIO in 2006, he was chief patent counsel for MGI Pharma Inc. in Bloomington, MN, and senior patent counsel for Guilford Pharmaceuticals Inc. in Baltimore, MD. Mr. Sauer holds a M.S. degree in biology from the University of Ulm in his native Germany, a Ph.D. in neuroscience from the University of Lund, Sweden, and a J.D. degree from Georgetown University Law Center, where he serves as adjunct professor.



Connect with [Hans](#) on LinkedIn

Andrew (A.J.) Tibbetts



Andrew (A.J.) Tibbetts is a partner at Greenberg Traurig LLP. Leveraging his technical proficiency and prior software engineering career, he provides business-oriented IP legal counseling for software, AI and electronics-based technologies. His strategic approach incorporates open source practices and trade secret policies alongside patents, and he advises clients on licensing, enforcement, diligence, and defense against infringement accusations. A.J. counsels traditional software and electronics companies, including artificial intelligence and machine learning (AI/ML) across a variety of domains. As “software eats the world,” a growing number of companies look to A.J. for advice protecting new investments in software and data science, including life sciences, biopharma, medtech, medical devices, radiology, digital health, health care IT, and healthtech companies.

Connect with [Andrew](#) on LinkedIn

Thank you for joining us.

2024 Advanced Life Sciences Institute Agenda: [LINK](#)

Connect with BCLT on [LinkedIn](#)